Milvexian

Milvexian
Clinical data
Other namesBMS-986177, JNJ-70033093
Routes of
administration
By mouth
ATC code
  • None
Legal status
Legal status
  • Investigational
Pharmacokinetic data
Elimination half-life11.4–18.1 h
Identifiers
  • (9R,13S)-13-{4-[5-Chloro-2-(4-chloro-1H-1,2,3-triazol-1-yl)phenyl]-6-oxo-1(6H)-pyrimidinyl}-3-(difluoromethyl)-9-methyl-3,4,7,15-tetraazatricyclo[12.3.1.02,6]octadeca-1(18),2(6),4,14,16-pentaen-8-one
CAS Number
PubChem CID
DrugBank
ChemSpider
UNII
KEGG
ChEMBL
Chemical and physical data
FormulaC28H23Cl2F2N9O2
Molar mass626.45 g·mol−1
3D model (JSmol)
  • C[C@@H]1CCC[C@H](n2cnc(-c3cc(Cl)ccc3-n3cc(Cl)nn3)cc2=O)c2cc(ccn2)-c2c(cnn2C(F)F)NC1=O
  • InChI=1S/C28H23Cl2F2N9O2/c1-15-3-2-4-23(20-9-16(7-8-33-20)26-21(36-27(15)43)12-35-41(26)28(31)32)39-14-34-19(11-25(39)42)18-10-17(29)5-6-22(18)40-13-24(30)37-38-40/h5-15,23,28H,2-4H2,1H3,(H,36,43)/t15-,23+/m1/s1
  • Key:FSWFYCYPTDLKON-CMJOXMDJSA-N

Milvexian is a factor XIa inhibitor anticoagulant drug. It is taken by mouth. As of late 2021, it was under study for the prevention of blood clots in patients undergoing surgery. In 2018–2023, Bristol-Myers Squibb studied milvexian for the prevention of stroke.